Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 596 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Withdrawal Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior

NCT03840694
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Withdrawal
Interventions
Smoking Abstinence, Ad Lib Smoking
Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

A Physical Dependence Study in Schizophrenia

NCT01452919
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Oakland, California • San Diego, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Days to 11 Months
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 25, 2026, 6:41 AM EDT
Terminated Phase 2Phase 3 Interventional

Mindfulness Training Plus Oxytocin Effects on Smoking Behavior

NCT03819231
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Oxytocin, Mindfulness, Saline Solution, Sham mindfulness
Drug · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 25, 2026, 6:41 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

BRIDGE Device for Treatment of Opioid Withdrawal

NCT04162145
View directory record Official record
Conditions
Opioid Withdrawal, Pain, Craving
Interventions
Active BRIDGE device placement, Inactive BRIDGE device placement
Device
Lead sponsor
BrightView LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Not applicable Interventional

Treatment for Caffeine Dependence

NCT01951872
View directory record Official record
Conditions
Caffeine Use Disorder (DSM-5 Condition for Further Study)
Interventions
Manual-based treatment for caffeine dependence
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 25, 2026, 6:41 AM EDT
Completed No phase listed Observational

Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence

NCT01034384
View directory record Official record
Conditions
Smoking Cessation
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 25, 2026, 6:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

NCT04214834
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Morphine, Methadone
Drug
Lead sponsor
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program
Network
Eligibility
36 Weeks and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 6:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Immune Tolerance Induction After Liver Transplantation

NCT07269041
View directory record Official record
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Not applicable Interventional

Heart Obesity Prevention Education

NCT02092545
View directory record Official record
Conditions
Obesity
Interventions
Ketogenic diet
Other
Lead sponsor
Tampa General Hospital
Other
Eligibility
25 Years to 64 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

NCT00661674
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Palonosetron, Hydroxyzine, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

NCT03573297
View directory record Official record
Conditions
Bipolar I Disorder, Mania, Depression
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
46
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Results available

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

NCT03891862
View directory record Official record
Conditions
Tardive Dyskinesia (TD)
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 25, 2026, 6:41 AM EDT
Not listed Phase 2 Interventional

Growth Hormone Replacement Therapy for Retried Professional Football Players

NCT04121780
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Interventions
Growth Hormone, Placebo
Biological · Other
Lead sponsor
Center for Neurological Studies
Other
Eligibility
18 Years to 76 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

NCT00113269
View directory record Official record
Conditions
Kidney Transplantation
Interventions
basiliximab, rabbit anti-thymocyte globulin, tacrolimus, alemtuzumab, mycophenolate mofetil, steroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Results available

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

NCT04008069
View directory record Official record
Conditions
Sarcoidosis
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Results available

Lofexidine for Adults Undergoing Lumbar Spine Surgery

NCT04126083
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Lofexidine Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 25, 2026, 6:41 AM EDT
Terminated Early Phase 1 Interventional Results available

Research Study of ATG and Rituximab in Renal Transplantation

NCT01318915
View directory record Official record
Conditions
Renal Transplant Recipients
Interventions
ATG, Rituximab, Tacrolimus, Sirolimus, MMF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00218218
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 25, 2026, 6:41 AM EDT
Terminated Phase 3 Interventional

Study of Probuphine in Patients With Opioid Dependence

NCT00772785
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Not applicable Interventional

An App to Aid in Transitioning Off Opioid Medication

NCT03077932
View directory record Official record
Conditions
Opiate Use Disorder, Opiate Withdrawal Syndrome
Interventions
App Development and Open Pilot
Other
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 25, 2026, 6:41 AM EDT
Completed No phase listed Observational Results available

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

NCT01535664
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Withdrawal of dalfampridine-ER 10mg
Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder

NCT04092101
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Cigarettes with varying nicotine content, E-Cigarettes
Other
Lead sponsor
University of Vermont
Other
Eligibility
21 Years to 70 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 25, 2026, 6:41 AM EDT
Completed Not applicable Interventional Results available

SRL (Sirolimus) Withdrawal

NCT02062944
View directory record Official record
Conditions
Acute Rejection of Liver Transplant, Effects of Immunosuppressant Therapy
Interventions
Sirolimus
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 25, 2026, 6:41 AM EDT